Publications

Pubmed link:

https://pubmed-ncbi-nlm-nih-gov.proxy3.library.mcgill.ca/?term=lebrun+jj

Recent publications:

• Dai M, Yan G, Wang N, Daliah G, Edick A, Poulet S, Boudreault J, Ali S, Burgos S, Lebrun JJ. (2021) In vivo Genome-Wide CRISPR Screen Reveals Breast Cancer Vulnerabilities and synergistic mTOR/Hippo Targeted Combination Therapy. Nature Communications 12, Article number: 3055, published May 24, 2021).
• Yan G, Dai M, Zhang C, Poulet S, Moamer A, Wang N, Boudreault J, Ali S, Lebrun JJ. (2021) TGFβ/Cyclin D1/Smad-mediated inhibition of BMP4 promotes breast cancer stem cell self-renewal activity. Oncogenesis 2021 Mar 1;10(3):21. doi: 10.1038/s41389-021-00310-5
• Tian J, Wang V, Wang N, Khadang B, Bakdounes K, Ali S, Lebrun JJ. (2021) Identification of MFGE8 and KLK5/7 as mediators of breast tumorigenesis and resistance to COX-2 inhibition. Breast Cancer Research 2021 Feb 15;23(1):23. doi: 10.1186/s13058-021-01401-2.
• Shams A, Binothman N, Boudreault J, Wang N, Shams F, Hamam D, Tian J, Moamer A, Dai M, Lebrun JJ, Ali S. (2021). Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis. Oncogenesis 2021 Jan 14;10(1):10. doi: 10.1038/s41389-020-00297-5.PMID: 33446633.
• Dai M, Boudreault J, Wang N, Poulet S, Daliah G, Yan G, Moamer A, Burgos S, Sabri S, Ali S, Lebrun JJ. (2021) Differential regulation of cancer progression by CDK4/6 plays a central role in DNA replication and repair pathways. Cancer Res 2020 Dec 28: canres.2121.2020. doi: 10.1158/0008-5472.CAN-20-2121. Online ahead of print.PMID: 33372040.
• Hachim IY, López-Ozuna VM, Hachim MY, Lebrun JJ, Ali S (2019) Prolactin Hormone Exerts Anti-Tumorigenic Effects in HER-2 Overexpressing Breast Cancer Cells through Regulation of Stemness Stem Cell Res. 2019 Aug 18;40:101538. doi: 10.1016/j.scr.2019.101538. PMID: 31450192
• López-Ozuna VM, Hachim I, Hachim M, Lebrun JJ, Ali S. (2019) Prolactin modulates TNBC aggressive phenotype limiting tumorigenesis. Endocrine-Related Cancer 26:3, pp321-327. PMID: 30640712.
• Moamer A, Hachim IY, Binothman N, Wang N, Lebrun JJ, Ali S. (2019) A role for kinesin-1 subunits KIF5B/KLC1 in regulating epithelial mesenchymal plasticity in breast tumorigenesis. EBioMedicine 2019 Jul;45:92-107. doi: 10.1016/j.ebiom.2019.06.009. Epub 2019 Jun 14. PMID: 31204277.
• Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells. Br J Cancer. Tian J, Raffa FA, Dai M, Moamer A, Khadang B, Hachim IY, Bakdounes K, Ali S, Jean-Claude B, Lebrun JJ. doi: 10.1038/s41416-018-0287-3
• Differential expression of TGFβ isoforms in breast cancer highlights different roles during breast cancer progression. Hachim MY, Hachim IY, Dai M, Ali S, Lebrun JJ. Tumour Biol. 2018 Jan;40(1):1010428317748254. doi: 10.1177/1010428317748254
• KiSS1 gene as a novel mediator of TGFβ-mediated cell invasion in triple negative breast cancer. Tian J, Al-Odaini AA, Wang Y, Korah J, Dai M, Xiao L, Ali S, Lebrun JJ. Cell Signal. 2018 Jan;42:1-10. doi: 10.1016/j.cellsig.2017.10.002. Epub 2017 Oct 6.
• Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration. Hachim IY, Villatoro M, Canaff L, Hachim MY, Boudreault J, Haiub H, Ali S, Lebrun JJ. Sci Rep. 2017 Nov 3;7(1):14976. doi: 10.1038/s41598-017-14549-9.
• CPSF6 is a Clinically Relevant Breast Cancer Vulnerability Target: Role of CPSF6 in Breast Cancer. Binothman N, Hachim IY, Lebrun JJ, Ali S. EBioMedicine. 2017 Jul;21:65-78. doi: 10.1016/j.ebiom.2017.06.023. Epub 2017 Jun 24.
• Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer. Tian J, Hachim MY, Hachim IY, Dai M, Lo C, Al Raffa F, Ali S, Lebrun JJ. doi:10.1038/srep40258
• Revealing determinant factors for early breast cancer recurrence by decision tree. Guo J, Fung BCM, Kuppen PJK, Tollenaar RAEM, Mesker WE, and Lebrun JJ. Information Systems Frontiers (ISF), 13 pages, in press.
• CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer. Dai M, Zhang C, Ali A, Hong X, Tian J, Lo C, Fils-Aimé N, Burgos SA, Ali S, Lebrun JJ. Sci Rep. 2016 Oct 19;6:35383. doi: 10.1038/srep35383.
• Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy. López-Ozuna VM, Hachim IY, Hachim MY, Lebrun JJ, Ali S. Sci Rep. 2016 Aug 2;6:30934. doi: 10.1038/srep30934.
• Cell-specific optoporation with near-infrared ultrafast laser and functionalized gold nanoparticles. Bergeron E, Boutopoulos C, Martel R, Torres A, Rodriguez C, Niskanen J, Lebrun JJ, Winnik FM, Sapieha P, Meunier M. Nanoscale. 2015 Nov 14;7(42):17836-47. doi: 10.1039/c5nr05650k. Epub 2015 Oct 13.
• Prolactin/Jak2 directs apical/basal polarization and luminal linage maturation of mammary epithelial cells through regulation of the Erk1/2 pathway. Liu F, Pawliwec A, Feng Z, Yasruel Z, Lebrun JJ, Ali S. Stem Cell Res. 2015 Sep;15(2):376-83. doi: 10.1016/j.scr.2015.08.001. Epub 2015 Aug 11.
• Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer. Hachim IY, Hachim MY, Lopez VM, Lebrun JJ, Ali S. Appl Immunohistochem Mol Morphol. 2016 Apr;24(4):238-45. doi: 10.1097/PAI.0000000000000178.
• The Retinoblastoma Tumor Suppressor Protein (pRb)/E2 Promoter Binding Factor 1 (E2F1) Pathway as a Novel Mediator of TGFβ-induced Autophagy. Korah J, Canaff L, Lebrun JJ. J Biol Chem. 2016 Jan 29;291(5):2043-54. doi: 10.1074/jbc.M115.678557. Epub 2015 Nov 23.
• A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome. Hachim IY, Shams A, Lebrun JJ, Ali S. Hum Pathol. 2016 Jul;53:142-52. doi: 10.1016/j.humpath.2016.02.010. Epub 2016 Mar 14.
• A dual prognostic role for the TGFβ receptors in human breast cancer. Hachim IY, Hachim MY, Lopez-Ozuna VM, Ali S, Lebrun JJ.Hum Pathol. Jul 18. pii: S0046-8177(16)30143-5. doi: 10.1016/j.humpath.2016.07.002
• The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma. Humbert L, Ghozlan M, Canaff L, Tian J, Lebrun JJ. BMC Cancer. 2015 Mar 29;15:200. doi: 10.1186/s12885-015-1177-1
• Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes. Guo J, Canaff L, Rajadurai CV, Fils-Aimé N, Tian J, Dai M, Korah J, Villatoro M, Park M, Ali S, Lebrun JJ. Breast Cancer Res. 2014 Dec 13;16(6):476. doi: 10.1186/s13058-014-0476-9.
• Development of buffers for fast semidry transfer of proteins. Garić D, Humbert L, Fils-Aimé N, Korah J, Zarfabian Y, Lebrun JJ, Ali S. Anal Biochem. 2013 Oct 15;441(2):182-4. doi: 10.1016/j.ab.2013.07.009. Epub 2013 Jul 16.
• Visible and near infrared resonance plasmonic enhanced nanosecond laser optoporation of cancer cells. St-Louis Lalonde B, Boulais E, Lebrun JJ, Meunier M. Biomed Opt Express. 2013 Apr 1;4(4):490-9. doi: 10.1364/BOE.4.000490. Epub 2013 Mar 1.
• Activin and TGFβ regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells. Neel JC, Lebrun JJ. Cell Signal. 2013 Jul;25(7):1556-66. doi: 10.1016/j.cellsig.2013.03.013. Epub 2013 Mar 22
• MicroRNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1), a new signaling route through which transforming growth factor-β Mediates the migration and actin dynamics of breast cancer cells. Fils-Aimé N, Dai M, Guo J, El-Mousawi M, Kahramangil B, Neel JC, Lebrun JJ. J Biol Chem. 2013 Apr 26;288(17):11807-23. doi: 10.1074/jbc.M112.430934. Epub 2013 Mar 11.
• TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system. Humbert L, Lebrun JJ. Cell Signal. 2013 Feb;25(2):490-500. doi: 10.1016/j.cellsig.2012.10.011. Epub 2012 Oct 23.
• Baumgart J., Humbert L, Winnick F, Lebrun JJ, Meunier M (2012) Femtosecond laser induced plasmonic enhanced optoporation and transfection of melanoma cells. Biomaterials Mar;33(7):2345-50. IF 7.9.
• Dai M, AlOdaini A, Arakelian A, Rabbani S, Ali S, Lebrun JJ (2012) A novel function for p21 as a critical regulator of TGFß mediated breast cancer metastasis. Breast Cancer Res, 2012 Sep 20;14(5): R127. [Epub ahead of print]). Cited as highly accessed paper in biomed central
• Ma CI, Martin C, Ma Z, Lebrun JJ, Kiss RS (2012). The engulfment protein GULP is a regulator of transforming growth factor-beta response J Biol Chem, Jun 8;287(24):20636-51.
• Korah J, Falah N, Lacerte A, Lebrun JJ (2012). A transcriptionally active pRb-E2F1-P/CAF signaling pathway is central to TGFβ-mediated apoptosis, Cell Death and Disease, Nature Publishing Group, Vol 3. Pp 407
• Cocolakis E, Dai M, Drevet L, Ho J, Haynes E, Ali S, Lebrun JJ (2008) Smad signaling antagonizes Stat5-mediated cell growth and differentiation of mammary epithelial cells. (J. Biol Chem, 18;283(3):1293-307.
• Ho J, Cocolakis E, Dumas V, Posner B, Laporte SA, Lebrun JJ (2005) The G protein-coupled receptor kinase-2 is a TGF-inducible antagonist of TGF signal transduction. EMBO J 24(18):3247-58.
• Valderrama H, Cocolakis E, Lacerte A, Lee E-H, Krystal G, Ali S, Lebrun JJ. (2002) Activin/TGFβ induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nature Cell Biology 4 (12):963-9.
• Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN. (2001) Inactivation of Menin, a Smad3-interacting protein, blocks TGF signaling. Proc.Natl.Acad.Sci USA 98, 3837-3842.
• Cocolakis E, Lemay S, Ali S, Lebrun JJ (2001) The p38 MAP Kinase pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J. Biol. Chem. 276, 18430-18436.